Recent Updates
Recently added Catalysts
RKTO Positive Sentiment

Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

Tuesday, May 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Hoth Therapeutics has been granted a U.S. patent for its HT-KIT oncology platform, which focuses on cancer treatment. The patent covers composition-of-matter and methods aimed at reducing the surface expression of the high-affinity IgE receptor. This development enhances the company's intellectual property position and supports its ongoing mast cell program.

Market Sentiment Analysis

POSITIVE FACTORS

  • Hoth Therapeutics awarded a U.S. patent for its HT-KIT oncology platform.
  • The patent strengthens the intellectual property foundation of the HT-KIT program.
  • The technology targets MS4A6A pre-mRNA splicing, potentially improving cancer treatment.

Full Press Release Details

Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform PR Newswire Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell Program HOBOKEN, N.J. , May 26, 2026 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“Hoth” or the “Company”), a clinical-stag…
You can read the full content here
The post Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform appeared first on Rocket One, Inc. .

Frequently Asked Questions

What is the HT-KIT oncology platform?

The HT-KIT oncology platform is a cancer-fighting technology developed by Hoth Therapeutics.

What does the U.S. patent cover?

The patent covers composition-of-matter and methods targeting MS4A6A pre-mRNA splicing.

How does the patent benefit Hoth Therapeutics?

The patent strengthens the intellectual property foundation of Hoth's HT-KIT mast cell program.

What is the significance of MS4A6A in cancer treatment?

MS4A6A targeting aims to reduce the surface expression of the high-affinity IgE receptor.

ShareAdd on Google
Tags: RKTO Viatris Investor Conferences Healthcare Hoth Therapeutics HT-KIT cancer treatment U.S. patent MS4A6A
Last updated: May 26, 2026

Biotech snapshot

Cash runway
$4M liquidity · $1M/mo burn
~1 mo
High dilution risk